The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is mobilizing and expanding the focus of the RADx® Independent Test Assessment Program (ITAP) to increase availability of high-quality, accurate, and reliable Mpox Virus diagnostic tests. NIBIB plans to provide in-kind analytical and clinical testing required by the U.S. Food and Drug Administration (FDA) to accelerate test validation and regulatory review of molecular and antigen-based point-of-care (POC) or home diagnostic tests and home collection tests. These efforts will facilitate rapid production and commercialization of Mpox Virus tests in the U.S.
Read more about the program at https://www.poctrn.org/itap-for-monkeypox.
What Is VentureWell’s Role in ITAP for Mpox?
VentureWell serves as a critical facilitator within the ITAP for Mpox program, leveraging its network and expertise to identify, assess, select, and contract vendors and professional service consultants.
VentureWell’s role includes providing vital infrastructure support and commercialization services for Mpox diagnostic innovators, to help accelerate the validation, regulatory authorization, and commercialization of innovative POC or home tests that can directly detect Mpox Virus and home collection tests for Mpox Virus testing.